In lung cancer, approximately 50% of a cohort of NSCLC patients elicited both CD4+ and CD8+ T-cell responses against SOX2 and the responses were readily detectable in the peripheral blood mononuclear cells. This evidence concerns the gene SOX2 and lung carcinoma.